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Abstract
Diabetic foot ulceration poses a heavy burden on the patient and the
healthcare system, but prevention thereof receives little attention. For every
euro spent on ulcer prevention, ten are spent on ulcer healing, and for every
randomized controlled trial conducted on prevention, ten are conducted on
healing. In this article, we argue that a shift in priorities is needed. For the
prevention of a first foot ulcer, we need more insight into the effect of interven-
tions and practices already applied globally in many settings. This requires
systematic recording of interventions and outcomes, and well-designed
randomized controlled trials that include analysis of cost-effectiveness. After
healing of a foot ulcer, the risk of recurrence is high. For the prevention of a
recurrent foot ulcer, home monitoring of foot temperature, pressure-relieving
therapeutic footwear, and certain surgical interventions prove to be effective.
The median effect size found in a total of 23 studies on these interventions is
large, over 60%, and further increases when patients are adherent to treat-
ment. These interventions should be investigated for efficacy as a state-of-
the-art integrated foot care approach, where attempts are made to assure
treatment adherence. Effect sizes of 75–80% may be expected. If such state-
of-the-art integrated foot care is implemented, the majority of problems with
foot ulcer recurrence in diabetes can be resolved. It is therefore time to act
and to set a new target in diabetic foot care. This target is to reduce foot ulcer
incidence with at least 75%. Copyright © 2016 John Wiley & Sons, Ltd.
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Introduction
Diabetic foot disease poses a heavy burden on the patient and the healthcare
system. Nearly 600 million people worldwide are expected to have diabetes
mellitus in 2035 [1], of which about 50% will develop peripheral neuropathy
and 15–25% have been estimated to develop one or more foot ulcers [2,3].
Foot ulcers are a major risk factor for, and nearly always precede, foot infection
and amputation. Furthermore, foot ulcers reduce patient mobility and quality
of life. The estimated cost of treating a foot ulcer was approximately €10K in
one large European study [4]. Therefore, by far the most effective way to
prevent the heavy patient and economic burden is by preventing the foot ulcer.
It is then rather disappointing to notice that foot ulcer prevention receives little
attention, both in clinical practice and in scientific research. A shift in priority
is needed.
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Cost savings through prevention
Expenditure on diabetic foot care has been suggested to
be about a third of total resource utilization for treatment
of diabetes mellitus and its complications [5]. Of the total
expenditure on diabetic foot care, ulcer prevention repre-
sents only a fraction of the costs incurred for treatment of
the ulcer and its complications, in a ratio of approximately
one to ten: for every euro spent on prevention, ten are
spent on ulcer management [6,7]. If we consider one mil-
lion patients with diabetes and an annual 2.2% ulcer
incidence rate [8], total annual treatment costs for these
foot ulcers are €220m. About half of the cost of ulcer
treatment is spent on hospitalization and amputation
treatment [4]. That means that if proper ulcer treatment
would be able to prevent 20% of hospitalization and
amputation (an effect size generally shown in wound
healing studies) [9], total treatment costs would decrease
to €198m (€220m0.2×€110m). However, if 50% of
ulcers can be prevented with proper preventative care
(an average effect size shown in 30 controlled studies on
prevention) [10], costs for the same population of
patients can be reduced to €110m (0.5×€220m), a differ-
ence in saving of €88m per million persons with diabetes.
In support of this, a cost-utility simulation based on
Markov modelling showed that intensified preventative
care would be cost-effective in at-risk patients if a 25%
reduction in foot ulcer incidence is achieved [11]. In
addition, an analysis of US Medicaid health cost data
suggested that for each $1 saved by the elimination of
low-cost preventative services provided by podiatric
physicians, the associated increase in hospitalization
charges was $48 [12]. These analyses clearly show the
cost-saving potential of prevention.
Prevention underexposed in research
Of the 100 most recently published randomized con-
trolled trials (RCTs) on the diabetic foot listed in PubMed
as of 12 April 2015 (search terms ‘Diabetic foot’ and
‘RCT’), 62 are on ulcer healing and only six on ulcer
prevention (Figure 1). So, for every RCT on prevention,
ten are conducted on healing. A further disparity is that
trials on prevention are investigator initiated and most
often include the comparison of an intervention with
good-quality standard foot care, whereas trials on ulcer
healing are mostly industry driven, often assessing the
Figure 1. (A) Distribution of randomized controlled trials (RCTs) per outcome category among the 100 most recently published trials
on the diabetic foot in the PubMed database, as of 12 April 2015; (B) number of controlled studies (i.e. RCTs and non-randomized
controlled studies) on ulcer prevention, differentiated to first or recurrent ulcer as outcome, as identified in the 2015 International
Working Group on the Diabetic Foot systematic review on ulcer prevention [10]. PAD, peripheral artery disease; QoL, quality of life
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efficacy of another wound-care product in addition to
often badly defined foot care. Because the market
introduction of wound-care products does not formally
require proven efficacy, but only safe use, lower efficacy
can be expected from trials on these products. Compared
with prevention, this undermines the value for money
invested in research and in diabetic foot care.
Also, within the research topic of ulcer prevention, a
clear disparity is present: only three of the 30 controlled
studies identified in the 2015 International Working
Group on the Diabetic Foot (IWGDF) systematic review
on ulcer prevention focus specifically on a first foot ulcer
(Figure 1) [10]. Eight studies use a mixed population of
patients with and without ulcer history, while 19 studies
focus specifically on ulcer recurrence. This dominance of
studies on recurrence may exist because (1) patients
with ulcer history are at greatest ulcer risk, which
increases the relevance to study these patients, and (2)
trials on ulcer recurrence require fewer patients to
demonstrate efficacy given the higher expected event
rate. So, while screening and preventative treatment
for patients without foot ulcer history is common
practice in many settings, the evidence base supporting
such practice is meagre.
Can we prevent a first foot ulcer?
In all prospective studies and risk classifications, per-
sons with a previous foot ulcer are found to be at the
highest risk for future ulceration [13]. Reported ulcer
recurrence rates are 30–40% in the first year after an
ulcer episode [14,15], compared with 7.5% annual
incidence for patients with peripheral neuropathy and
no ulcer history [8]. Thus, if the first ulcer is prevented
or postponed, ulcer incidence rates will drop substan-
tially. Because the evidence base for prevention of a
first foot ulcer is practically non-existent [10], we need
to ask ourselves if we can prevent a first foot ulcer in
persons with diabetes.
A ‘no’ as an answer is rather unsatisfactory. It would
mean that while millions of persons with diabetes are
at risk for ulceration, we cannot intervene to prevent
the problems awaiting them. This does not reflect
current opinion and does not abide to consensus-based
standards of good-quality care. For ‘yes’ as an answer,
we have few clues as support. There are indications that
home monitoring of foot temperature, therapeutic
footwear, and advice within an education session that
patients adhere to can help [10]. Yet, patients may be
reluctant to accept such treatment considering they did
not yet experience a foot ulcer, and cost-effectiveness
may be an issue because ulcer incidence rates are
relatively low. These few clues being unsatisfying on its
own, we call out for action: healthcare providers and
researchers should combine efforts to build up an evidence
base on prevention of a first foot ulcer.
We need more insight in the effect of interventions
and practices already applied globally in many settings.
Some of these have been studied, such as foot screen-
ing, treatment of pre-signs of foot ulceration, advice
on proper footwear, and patient education, and are
listed in the IWGDF Guidance on Prevention [16], but
the use of these interventions is based on low quality
of evidence or expert opinion. A better understanding
requires recording of interventions and outcomes in a
systematic way, as a form of practice-based evidence,
to initially progress our understanding on effective
treatment. Furthermore, it requires well-designed
large-sample studies on cost-effectiveness.
Recurrent foot ulcers: 75% are
preventable
Because of the high risk involved, prevention of ulcer
recurrence is one of the most important current topics in
diabetic foot disease. But why is it so difficult to prevent
a foot ulcer from recurring [17]? One reason is that
patients consider themselves, or are considered by their
caregiver, not to have a foot problem after they heal from
a foot ulcer, while we know they have. We therefore agree
with colleagues on a change in syntax in diabetic foot
care, where prevention equals ‘remission’, to increase
awareness for the foot problem and to promote the need
for adequate follow-up and foot care [18]. Another reason
is that many precipitating factors that caused the ulcer in
the first place, such as peripheral neuropathy, foot
deformity, and increased plantar barefoot pressure, have
not been resolved after healing (unless the foot is
operated on). A third reason is that the transition from a
healing device such as a walker or total contact cast to a
prevention modality such as therapeutic footwear likely
increases plantar pressure at the healed ulcer location
and therefore risk of recurrence. A fourth reason is
professional non-adherence to provide recommended
treatment, including foot care, therapeutic footwear, and
patient education [19]. A final reason is patient non-
adherence to follow advice on proper foot care or to wear
therapeutic footwear [20]. All these reasons reduce
efficacy in the prevention of ulcer recurrence.
The 2015 IWGDF systematic review on ulcer prevention
[10] shows there is some evidence to support integrated
foot care, consisting of a combination of professional foot
care, patient education, and therapeutic footwear, in the
prevention of ulcer recurrence. Self-management is
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considered important but has only been studied
sufficiently and proven effective for the home monitoring
of foot skin temperatures as a diagnostic method, in
combination with proper follow-up when necessary.
Studies on patient education show that while knowledge
of foot problems and foot care behaviour can improve,
ulcer recurrence is not prevented by limited (i.e. one or
two sessions) education. There is now high-quality
evidence to support the use of therapeutic footwear that
has a demonstrated pressure-relieving effect and that is
consistently worn by the patient. Finally, foot surgery can
be effective in selected patients, but more well-designed
studies are needed before definitive statements about
safety and efficacy can be made.
Particularly interesting is to assess the potential
cumulative preventative effect of these interventions.
In Table 1, the median effect sizes for all identified
controlled studies in the 2015 IWGDF systematic
review on ulcer prevention [10] in each of the five
aforementioned intervention categories are shown.
Except for patient education, the median effect sizes
demonstrate to be large, over 60% in three categories,
showing their large potential for prevention. For
integrated foot care, effect sizes found are <50%, but
these are from studies that did not include state-of-the-
art interventions. Therefore, one can imagine the effect
that may be achieved when effective state-of-the-art
single interventions are combined in an integrated foot
care approach: a 75–80% reduction in ulcer recurrence
incidence seems possible, although this should be demon-
strated in properly designed randomized controlled trials.
If confirmed, and if such a state-of-the-art integrated
approach is implemented in diabetic foot care, the vast
majority of foot problems after healing of the ulcer can
be prevented, and with that the large burden of foot ulcer
recurrence in diabetes.
Adherence
Treatment adherence has clearly been shown in the 2015
IWGDF systematic review on ulcer prevention to be a signif-
icant factor in outcome [10]. Each of a total eight studies
that investigated the effect of adherence on ulcer preven-
tion showed that patients who are adherent to advice
given, to undergoing professional care, to monitoring their
foot temperatures, or to wearing their therapeutic foot-
wear, have significantly better outcomes than those who
are non-adherent. Table 1 shows the mean effect sizes
from these studies for the four intervention categories
where adherence plays a role. Effect sizes are large in all
categories, ranging from 58% to 98%. Interestingly, while
the data on efficacy of patient education shows no general
effect, positive outcomes are obtained for patients who are
adherent to the advice given within the education
program. Combining the effect sizes found on treatment
adherence with those found on treatment efficacy further
supports the large potential in preventative care. This
strengthens the proposition that problems with foot ulcers
and their complications can be mostly prevented when
effective interventions are used in an appropriate way.
For this reason, non-adherence should be discussed with
patients and should guide treatment choices in clinical
practice, much more than is currently the case. It remains
a challenge how we can achieve better adherence. It starts
with knowing and understanding why a patient does not
adhere to a given intervention. For the topic of footwear
adherence, these reasons have been explored, but more effort
is needed in this area [20,21]. We found no studies in the
literature on the effect of interventions that aim to increase
treatment adherence in the diabetic foot, and no current
trials seem to be underway [10]. Therefore, investigations
into factors that determine adherence and into interven-
tions that aim to increase adherence are urgently needed.
Table 1. Effect sizes in foot ulcer risk reduction for five intervention categories as assessed for the 2015 International Working
Group on the Diabetic Foot systematic review on ulcer prevention [10]
Intervention category
Treatment efficacy Effect of treatment adherence
n Median effect sizea (%) Range (%) n Mean effect sizeb (%)
Integrated foot care 5 33.3 9.1 to 100 3 83.0
Self-management 4 66.2 5.4 to 90.0 1 98.0
Patient education 2 13.4 26.3 to 0.5 2 85.5
Therapeutic footwear 10 63.6 14.6 to 92.9 2 58.1
Foot surgery 9 70.8 10.4 to 100 0 —
State-of-the-art
integrated approach
75–80
The treatment efficacy of the state-of-the-art integrated approach is an estimated range of what may be achievable based on the effect
sizes of the single interventions if combined into a state-of-the-art integrated foot care approach.
n, number of controlled studies.
aMedian effect size presented as the percentage foot ulcer risk reduction in the group of patients in the intervention arm compared with
the control arm receiving usual care.
bMean effect size, presented in percentage foot ulcer risk reduction in patients who are adherent to treatment, when compared with pa-
tients who are non-adherent to treatment.
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A new International Working Group on
the Diabetic Foot risk classification
Persons with a previous foot ulcer are in the highest risk
category of current risk classifications [2]; for the IWGDF
risk classification, this is grade 3. However, in daily clini-
cal practice, a large variation in disease severity exists
within this risk group of patients. Some patients continu-
ously recur, whereas others have only one ulcer episode
in their life. Differentiation in disease severity within this
risk category, with a corresponding differentiation in level
of preventative care, seems indicated.
Factors that can be considered for more differentiation
in risk are available from prospective studies on ulcer re-
currence. These factors can be divided into foot-specific
factors (e.g. previous ulcer location [22,23], presence
of minor lesions [24], and amputation history [25]), bio-
mechanical factors (e.g. barefoot peak plantar pressure
[24,26] and in-shoe peak plantar pressure [24]),
biomedical factors (e.g. presence of peripheral artery
disease [22,23], HbA1c [23], osteomyelitis of the healed
ulcer [23], and elevated C-reactive protein [23]), and
behavioural factors (most notably adherence [24]).
While some prospective risk factor studies have com-
bined several of these factors [24], a comprehensive
multivariate analysis still remains to be conducted. Such
analyses on large sample sizes can establish more
certainty on the relative role of these factors and, subse-
quently, may help in developing a more detailed risk
classification system.
An important aspect to be considered in any future
study on recurrence is where the ulcer develops. In line
with the IWGDF risk classification, we defined a ‘recurrent
ulcer’ in the 2015 IWGDF systematic review on ulcer pre-
vention as any ulcer after healing of a first ulcer, regard-
less of location on the foot [10]. Because none of the
studies on recurrence provide specific information on
whether the new ulcer developped at the same location
as the previous one, another definition was not possible.
Nevertheless, an ulcer that develops at a metatarsal head
6 months after healing of an ulcer at the very same loca-
tion is clinically clearly different to an ulcer in the same
patient that develops after 2 years on the dorsal side of
the contralateral foot. To better understand foot ulcera-
tion and to better predict outcome in the highest risk
group, we ought to take this difference into account.
Investigations in this area require long-term recording of
treatment provided, patient characteristics, and presence,
location, and timing of a foot ulcer. Setting up such
registries for such recording has proven possible for
various aspects of medicine (e.g. surgical registries and
cancer registries) and should therefore be possible for foot
ulcers in diabetes.
What should we be doing?
To better inform clinicians and practitioners about
effective treatment to prevent a first foot ulcer, we need
large-scale registries on treatment in daily practice to
establish a practice-based evidence base and, in addition,
well-designed controlled studies in first line of care that
take cost aspects into account.
To prevent foot ulcer recurrence, we need to (better)
implement currently available state-of-the-art knowledge
from well-designed RCTs. The new IWGDF Guidance on
Prevention provides clinicians and practitioners with various
recommendations on proper preventative care that can, if
implemented, have a huge positive impact on the patient,
economic, and social burden of diabetic foot disease [16].
We hope the following research agenda will guide
researchers, clinicians, and funding bodies in prioritizing
their limited resources.
• RCTs on the cost-effectiveness of interventions to prevent
a first foot ulcer.
• Studies on the effect of interventions on incidence of
first foot ulcer through a practice-based approach by
setting up data registries in first-line foot care.
• RCTs on the (cost-)effectiveness of a state-of-the-art
integrated foot care program to prevent foot ulcer
recurrence.
• RCTs on the effectiveness of interventions to improve
treatment adherence, and of improved adherence on
foot ulcer incidence.
• Comprehensive analyses of predictive factors of foot
ulcer recurrence from large-scale data registries that
include biomedical, biomechanical, and behavioural
factors.
• Studies on the effectiveness of using different time
intervals for foot screening for risk factors, so as to deter-
mine the optimal time frequency for foot screening.
Conclusions
In this article, we have presented the cost-saving potential
of preventative foot care, the gaps in our knowledge on
ulcer prevention, the disparity in focus between ulcer
prevention and ulcer healing, and the enormous potential
in the prevention of foot ulcer recurrence in diabetes. We
now need to shift priority in diabetic foot care and research
to the prevention of foot ulcers. Two important actions in
preventative foot care are a) to do what we say we should
be doing, that is, to implement knowledge in daily foot
care, and b) to improve treatment adherence. If we can
achieve this, an enormous positive effect in ulcer preven-
tion can be expected. International societies such as the
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International Diabetes Federation and IWGDF stress the
burden of lower-extremity amputation in diabetes and
have set goals to reduce amputation incidence by at least
50% [27]. It is now time to act and to set a new target in
diabetic foot care. This target is to reduce foot ulcer inci-
dence with at least 75%.
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